Tag Archives: First

HUBER+SUHNER and McLaren Applied launch first 5G edge computing rail antenna

Now enabling 5G applications to run on trains, the HUBER+SUHNER SENCITY® Rail ACTIVE Rooftop antenna is the first-of-its-kind rail antenna that contains an embedded radio and compute module to offer increased data throughput to support 5G services. It is an all-in-one active antenna with a single ethernet cable input for power and data transmission. Travellers… Read More »

India’s Covid vaccine maker told to meet domestic demand first, urges ‘rest of the world’ to be patient

An AstraZeneca vaccine production line. Bloomberg | Bloomberg | Getty Images The world’s largest vaccine maker by volume, Serum Institute of India, has been told to meet domestic demand for Covid-19 shots first — before distributing them overseas. The move implies that foreign governments could face order delays from the company as it places India’s… Read More »

Gilead’s Veklury becomes first FDA-approved drug for treating COVID-19

Dive Brief: The Food and Drug Administration has granted a full approval to Gilead’s COVID-19 drug Veklury, making it the first medicine to win a standard clearance from the agency to treat the disease caused by the new coronavirus. The FDA authorized Veklury for emergency use in May, a declaration that’s only valid during a… Read More »

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma

PRINCETON, N.J.–(BUSINESS WIRE) October 2, 2020 — Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo (nivolumab) 360 mg every three weeks plus Yervoy (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) for the first-line treatment of adult patients with unresectable malignant pleural… Read More »